Compare GDOT & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GDOT | OCS |
|---|---|---|
| Founded | 1999 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 750.5M | 732.4M |
| IPO Year | 2010 | 2022 |
| Metric | GDOT | OCS |
|---|---|---|
| Price | $12.37 | $8.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | $16.13 | ★ $36.37 |
| AVG Volume (30 Days) | ★ 334.7K | 183.9K |
| Earning Date | 11-09-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.33 | N/A |
| Revenue | ★ $2,080,491,000.00 | N/A |
| Revenue This Year | $15.22 | N/A |
| Revenue Next Year | $6.73 | $365.20 |
| P/E Ratio | $37.39 | ★ N/A |
| Revenue Growth | ★ 20.69 | N/A |
| 52 Week Low | $10.10 | $9.00 |
| 52 Week High | $13.75 | $34.48 |
| Indicator | GDOT | OCS |
|---|---|---|
| Relative Strength Index (RSI) | 28.64 | 28.67 |
| Support Level | $11.95 | N/A |
| Resistance Level | $12.61 | $10.84 |
| Average True Range (ATR) | 0.25 | 0.49 |
| MACD | -0.09 | -0.06 |
| Stochastic Oscillator | 42.13 | 9.78 |
Green Dot Corp is a financial technology company that provides financial services for consumers in the United States without good banking options. It has three segments Consumer Services, Business to Business Services(B2B), and Money Movement Services. The company generates maximum revenue from B2B segment. Its B2B Services segment consists of revenues and expenses derived from (i) its partnerships with prominent consumer and technology companies that make banking products and services available to their consumers, partners and workforce through integration with its banking platform (the "Banking-as-a-Service", or "BaaS channel"), and (ii) a comprehensive payroll platform that it offers to corporate enterprises (the "Employer channel") to facilitate payments for todays workforce.
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.